Health Canada has approved Merus Labs wound care product Collacare which is indicated for the management of ulcers, burns, split-skin donor sites and other dermal wounds.
Collacare is a biodegradable, implantable advanced wound care device made up of bioactive collagen dressing.
The product is licensed to Merus Labs by Innocoll, a developer and manufacturer of pharmaceutical products and medical devices using its proprietary collagen-based technologies.
Collacare forms a gel-like sheet that assumes the shape of the wound bed so as to maintain a moist environment to aid the wound healing process.
Merus’ six wound care products consist of foam dressings, isolate hydrophilic dressings, excel hydrocolloid transparent wound dressings, tulip sacral ulcer wound dressing as well as, repel & spot wound dressings.
These products are indicated for pressure ulcers, trauma wounds, donor sites, diabetic ulcers, arterial venous ulcers as well as 1st and 2nd degree burns.
Merus Labs president and CEO Ahmad Doroudian said Collacare provides Canadian patients and health care providers with a biodegradable and implantable device that accelerates wound healing.
"We look forward to the launch of our line of wound care products in the next quarter," said Doroudian.